Panbela Therapeutics RSI
What is the RSI of Panbela Therapeutics?
The RSI of Panbela Therapeutics Inc. is 48.17
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with rsi similar to Panbela Therapeutics
- First Trust Exchange-Traded Fund III has RSI of 48.16
- World Index Shares ETFs - CSI HK 100 Tracker has RSI of 48.16
- Reliance Naval and Engineering has RSI of 48.16
- JH EDL Technology has RSI of 48.16
- Inter-Rock Minerals has RSI of 48.16
- Housing Development Finance has RSI of 48.16
- Panbela Therapeutics has RSI of 48.17
- Confederation Minerals has RSI of 48.18
- Apyx Medical has RSI of 48.18
- Sabre Corp has RSI of 48.18
- Esco Technologies has RSI of 48.18
- Primavera Capital Acquisition has RSI of 48.18
- Helen of Troy Ltd has RSI of 48.19